{"DataElement":{"publicId":"7171843","version":"2","preferredName":"Patient Metastatic Breast Carcinoma Diagnosis Confirmation Clinical Trial Eligibility Criteria Status","preferredDefinition":"A verification status to determine patient eligibility for the study protocol requirements of metastatic breast cancer.","longName":"ELIG_MBC_CONF","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"7169280","version":"1","preferredName":"Patient Metastatic Breast Carcinoma Diagnosis Confirmation Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._Having been established or verified._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2177068v1.0:7170144v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2177068","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"Patient","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AB6-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7170144","version":"1","preferredName":"Metastatic Breast Carcinoma Diagnosis Confirmation Clinical Trial Eligibility Criteria","preferredDefinition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.:A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.:The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.:Having been established or verified.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"7170144v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic","conceptCode":"C14174","definition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E906A28-AC23-56FE-E053-F662850AB443","latestVersionIndicator":"Yes","beginDate":"2020-02-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-14","modifiedBy":"ONEDATA","dateModified":"2020-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8AB436-9C3A-4975-E053-F662850A8783","latestVersionIndicator":"Yes","beginDate":"2020-02-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-14","modifiedBy":"TAYLORT","dateModified":"2020-02-26","changeDescription":"2/14/20 EA1183/tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5676955","version":"2","preferredName":"Confirmation Status","preferredDefinition":"Having been established or verified._A condition or state at a particular time.","longName":"CONFSTAT","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"11","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unconfirmed","valueDescription":"Negation Confirmation","ValueMeaning":{"publicId":"5676956","version":"1","preferredName":"Negation Confirmation","longName":"5676956","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Having been established or verified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49380D88-AB51-745A-E053-F662850AA135","latestVersionIndicator":"Yes","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE40-165A-E053-4EBD850AA952","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"},{"value":"Confirmed","valueDescription":"Confirmation","ValueMeaning":{"publicId":"3953314","version":"1","preferredName":"Confirmation","longName":"3953314","preferredDefinition":"Having been established or verified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A874-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"RODGERSC","dateCreated":"2013-11-18","modifiedBy":"TSESU","dateModified":"2019-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE4A-165A-E053-4EBD850AA952","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"},{"value":"N/A","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5043360","version":"1","preferredName":"Not Applicable","longName":"5043360","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2421E11B-65A6-151D-E050-BB89AD4378BB","latestVersionIndicator":"Yes","beginDate":"2015-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-09","modifiedBy":"DWARZEL","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A7BA8394-AE54-165A-E053-4EBD850AA952","beginDate":"2020-02-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7329879","version":"1","preferredName":"Confirmation Status","preferredDefinition":"Having been established or verified.:A condition or state at a particular time.","longName":"C25458:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Confirmation","conceptCode":"C25458","definition":"Having been established or verified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BA8394-AE19-165A-E053-4EBD850AA952","latestVersionIndicator":"Yes","beginDate":"2020-06-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7BA8394-AE2A-165A-E053-4EBD850AA952","latestVersionIndicator":"Yes","beginDate":"2017-02-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-10","modifiedBy":"TAYLORT","dateModified":"2020-06-12","changeDescription":"6/10/20 tmt versioned to 2.0 for changes to Long and Short names.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient has histologically co","type":"Preferred Question Text","description":"Patient has histologically confirmed metastatic breast cancer by local assessment that is hormone receptor positive by ASCO/CAP guidelines and has known HER2 status.","url":null,"context":"ECOG-ACRIN"},{"name":"EA1183 - 1","type":"Alternate Question Text","description":"Patient must have radiographically confirmed metastatic breast cancer with histologic confirmation of either metastatic or primary tumor biopsy by local assessment that is hormone receptor positive by ASCO/CAP guidelines and has known HER2 status.","url":null,"context":"ECOG-ACRIN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D4A25B-3831-566A-E053-4EBD850AA9EA","latestVersionIndicator":"Yes","beginDate":"2020-02-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-06-11","modifiedBy":"KUMMEROA","dateModified":"2021-08-20","changeDescription":"6/11/20 CDE versioned for updated VD; tmt. 2/26/20 tmt released.; 2/17/20 EA1183; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}